Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

The effect of a low glycemic load (GL) diet on insulin-like growth factor-1 (IGF-1) concentration is still unknown but may contribute to lower chronic disease risk.

The researchers aimed to assess the impact of GL on concentrations of IGF-1 and IGF-binding protein-3 (IGFBP-3).

Who Took Part

The study group was 80 participants.

By PubMed's age tags, the people studied were young adults and adults, both men and women.

The researchers conducted a randomized, controlled crossover feeding trial in 84 overweight obese and normal weight healthy individuals using two 28-day weight-maintaining high- and low-GL diets.

In all 80 participants completed the study and 20 participants completed post-prandial testing by consuming a test breakfast at the end of each feeding period.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between IGF-1 LR3 and the comparison at some point, usually with a gap in between.

Measures were fasting and post-prandial concentrations of insulin, glucose, IGF-1 and IGFBP-3.

The researchers used paired t-tests for diet component and linear mixed models for biomarker analyses.

What Was Measured

Topics PubMed links to this paper include Algorithms, Biomarkers, Blood Glucose, Body Mass Index, Dietary Carbohydrates, Glycemic Index and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized and crossover study of IGF-1 LR3 in 80 participants.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (European journal of clinical nutrition), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.